Contact

Peptide Tools to Study SARS-CoV-2

About SARS-CoV-2

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), the causative agent of Covid-19, is responsible for the current pandemic. Developing vaccines and therapies that are safe, effective, and rapidly deployable is an urgent global health priority.

JPT's Peptide Tools to Study SARS-CoV2

The global research efforts as well as clinicial trials evaluating vaccines and drugs generates a demand for SARS-CoV-2 related peptide products enabling definition of immune-relevant antigens, identification of B- and T-cell epitopes, development of therapeutic & diagnostic strategies and clinical trial immune monitoring.
In response, JPT has launched a broad development program to provide access to genome spanning SARS-CoV-2 peptide tools for applications such as:

  • SARS-CoV-2 clinical trial immune monitoring
  • SARS-CoV-2 correlation of cellular and humoral immune responses
  • SARS-CoV-2 evaluation of cross reactivities
  • SARS-CoV-2 vaccine target identification
  • SARS-CoV-2 blood and sero test development
  • SARS-CoV-2 T-and B-cell epitope discovery

We have broadened our portfolio of coronavirus related products beyond SARS-CoV-2, including SARS-CoV, MERS-CoV and common cold viruses CoV 229E, OC43, HKU1 and NL63. Have a look!

Cellular Immunity

PepMix™ Peptide Pools for

  • Antigen-specific T-cell stimulation
  • Cellular immune monitoring
  • Vaccine target discovery
  • Blood test development
  • Cross reactivity testing (SARS-CoV-2 vs. SARS, MERS, HCoV 229E, OC43…)
  • Cell therapy development

> SARS-CoV-2, -HCoV & other PepMixes™
> Customized & Clinical PepMix™ Pools
> Control Pools

Epitope Mapping Peptide Sets (EMPS)

  • Efficient epitope mapping and identification
  • Matrix Pools and individual peptides spanning a whole antigen in one set
  • Minimal sample amount required

> Product Page

Antigen Peptides for

  • Antigen specific T-cell stimulation in T-cell assays (i.e. ELISpot, ICS)
  • Immune monitoring
  • Proliferation assays
  • T-cell expansion

> Product Page

Humoral Immunity

RepliTope™ Pan Coronavirus for

  • Humoral immune monitoring
  • Antibody epitope discovery
  • Cross reactivity testing (SARS-CoV-2 vs. SARS, MERS, HCoV 229E, OC43…)
  • Seromarker discovery

> RepliTope™ Pan Coronavirus
>
Customized PepStar™ Peptide Microarrays

Multiwell RepliTopes™ SARS-CoV-2

  • Immune monitoring
  • Antibody epitope discovery
  • Screening individual antigens of SARS-CoV-2 and SARS
  • Seromarker discovery

> RepliTope™ Multiwell Microarrays

Antibody Response Profiling

  • Thousands of peptides spanning the entire SARS-CoV-2 genome using smallest sample volumes
  • Incubation using smallest sample volumes
  • Study of antibody cross-reactivities between SARS-CoV-2 and other corona viruses
  • Verification of peptide binders with a large numbers of samples
  • Transfer of results to ELISA platform for rapid test development

> Antibody Response Profiling

Peptide ELISA

  • Peptide ELISA development and service using SARS-CoV-2 peptides or a combination with other corona viruses
  • ELISA-based validation service of peptide binders identified by using JPT’s peptide microarray platform
  • Collaborative ELISA test development

> Peptide ELISA

Clinical Trial Immune Monitoring & Cell Therapy

Clinical Grade Peptides & PepMix™ Peptide Pools

  • High quality chemically synthesized antigen source for vaccine trial monitoring
  • Ancillary reagents for cellular therapy development
  • Full analytical coverage, stability testing, batch documentation and more

> Clinical Peptides & PepMix™ Peptide Pools™

Proteomics

SpikeMix™ SARS-CoV-2 for

  • Identify SARS CoV-2 antigens from biological samples
  • Mass spectrometry based assays (MRM)
  • Screen 23 proteotypic peptides from SARS-CoV-2

> SpikeMix™ SARS-CoV-2

References with SARS-CoV-2 Peptide Tools

T Cell and Antibody Responses to SARS-CoV-2: Experience From a French Transplantation and Hemodialysis Center During the COVID-19 Pandemic
Candon et al, Am J Transplant  (2020)
Intrafamilial Exposure to SARS-CoV-2 Induces Cellular Immune Response without Seroconversion
Gallais et al, Emerg Infect Dis (2020)
A Glimpse Into the Diverse Cellular Immunity Against SARS-CoV-2     
Chang  et al, Research Square (2020)
Immunogenicity of novel mRNA COVID-19 vaccine MRT5500 in mice and 2 non-human primates
Kalnin et al, bioRxiv (2020)
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in Older Adults
Anderson et al, NEJM (2020)
Divergent SARS-CoV-2-specific T and B cell Responses in Severe but Not Mild COVID-19
Oja et al, bioRxiv (2020)
Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates
Corbett et al, New England J of Med (2020)
Presence of SARS-CoV-2 reactive T cells in COVID-19 Patients and Healthy Donors
Braun et al, Nature (2020)
Single-shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Mercado et al, Nature (2020)
SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness
Corbett et al, bioRxiv (2020)
Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and Testing
Zecha et al, Mol Cell Proteomics (2020)
A Longitudinal Study of Immune Cells in Severe COVID-19 Patients
Payen et al, medRXiv (2020)
SARS-CoV-2-specific T cells Exhibit Unique Features Characterized by Robust Helper Function, Lack of Terminal Differentiation, and High Proliferative Potential
Neidleman et al, bioRxiv (2020)
Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in vitro by Intracellular Aminopeptidases
Stamatakis et al bioRxiv (2020)
Self-amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in Mice
McKay et al, Nature 2020
An mRNA Vaccine Against SARS-CoV-2 — Preliminary Report
Jackson et al, New England J of Med (2020)
SARS‐CoV‐2‐Reactive Interferon‐γ‐producing CD8+ T cells in Patients Hospitalized with Coronavirus Disease 2019
Giminez et al, J Med Vir (2020)
Concurrent Human Antibody and TH1 type T-cell Responses 2 Elicited by a COVID-19 RNA Vaccine
Sahin et al, medRXiv (2020)

Further references

 

 

Check our list of products,
click and go.

Quality Assurance

All production is performed according to ISO 9001:2015 standards

Stay in touch and be the first to receive the latest news!